Pulmonary Embolism (PE): Causes, Symptoms, Diagnosis, and Treatment

Pulmonary embolism (PE) is one of those medical emergencies that often arrives without warning, yet demands immediate attention. A small blood clot, usually formed in the legs, can travel through the bloodstream and suddenly block an artery in the lungs. When that happens, oxygen flow is disrupted, and the body is placed under intense stress.

The scale of this condition is more serious than many realize. Each year, hundreds of thousands of people worldwide are affected by pulmonary embolism. In the United States alone, estimates suggest that up to 900,000 cases of venous thromboembolism (including PE and deep vein thrombosis) occur annually, leading to 60,000 to 100,000 deaths. These numbers reflect not only how common it is, but how dangerous it can become when symptoms are missed or delayed.

What makes pulmonary embolism especially concerning is how easily it can be overlooked. Early signs such as shortness of breath, chest discomfort, or a sudden increase in heart rate may seem mild or be mistaken for less serious conditions. Yet behind those symptoms, a critical blockage may already be forming.

Understanding pulmonary embolism is not just about medical knowledge. It is about recognizing warning signs in time to act. The difference between early awareness and delayed response can be life-saving. In the sections ahead, you will explore the causes, symptoms, diagnostic methods, and treatment options for PE, helping you understand how to identify it and why quick action matters.

Table of Contents

What is Pulmonary Embolism?

Pulmonary embolism (PE) occurs when a blood clot blocks one or more arteries in the lungs, disrupting normal blood flow. Most commonly, this clot originates in the deep veins of the legs, a condition known as deep vein thrombosis (DVT), and then travels through the bloodstream to the lungs. Once lodged in a pulmonary artery, it can partially or completely block circulation, reducing oxygen levels in the blood and placing strain on the heart.

The severity of a pulmonary embolism depends on the size and number of clots. A small clot may cause mild symptoms or even go unnoticed, while a large or multiple clots can become life-threatening within a short period. When blood flow is obstructed, the affected portion of the lung cannot receive enough oxygen, which can lead to tissue damage and serious complications. Pulmonary embolism is considered a medical emergency because it can develop suddenly and worsen quickly. Without prompt treatment, it may lead to long-term lung damage, heart complications, or even death.

Types of Pulmonary Embolism

3 Main Types of Pulmonary Embolism

Pulmonary embolism can be classified into different types based on severity, size of the clot, and its impact on the heart and lungs:

Massive pulmonary embolism: This occurs when a large clot blocks a major artery in the lungs, leading to a sudden drop in blood pressure and severe strain on the heart. It is life-threatening and requires immediate emergency care.
Submassive pulmonary embolism: In this case, the clot does not cause a dramatic drop in blood pressure, but it still affects heart function and reduces oxygen levels. Patients may appear stable at first, yet complications can develop if not treated promptly.
Low-risk (or Non-massive) pulmonary embolism: These involve smaller clots that do not significantly affect heart function or blood pressure. Symptoms may be mild or moderate, but treatment is still necessary to prevent the condition from worsening.

A massive Pulmonary Embolism vs. A Submassive one

A massive Pulmonary Embolism differs from a submassive one based on its immediate impact on the body’s cardiovascular system, specifically its effect on blood pressure and heart function. The distinction is critical as it dictates the urgency and type of treatment required. The primary defining factor is the presence or absence of hemodynamic instability, which refers to the body’s inability to maintain adequate blood pressure and circulation.

A massive PE is the most severe and life-threatening classification. It is clinically defined by persistent hypotension (low blood pressure), with a systolic blood pressure below 90 mmHg for more than 15 minutes, or a drop in systolic blood pressure of at least 40 mmHg. This severe drop in blood pressure indicates that the clot (or clots) is so large that it is severely obstructing blood flow through the lungs, causing the heart to fail in its ability to pump blood effectively to the rest of the body. This state, known as obstructive shock, is a medical emergency requiring immediate, aggressive intervention, often involving powerful clot-busting drugs (thrombolytics) or surgical removal of the clot (embolectomy).

In contrast, a submassive PE (also known as an intermediate-risk PE) is one where the patient remains hemodynamically stable, meaning their blood pressure is normal. However, despite the stable blood pressure, the heart is showing signs of strain from having to pump against the blockage. This strain is referred to as right ventricular dysfunction.

It is diagnosed through evidence found on imaging tests like an echocardiogram (which may show the right ventricle of the heart is enlarged and not contracting properly) or through elevated levels of certain biomarkers in the blood, such as troponin or brain natriuretic peptide (BNP), which are released when the heart muscle is under stress. While not as immediately life-threatening as a massive PE, a submassive PE still carries a significant risk of deteriorating and requires close monitoring and standard anticoagulant treatment, with thrombolytics sometimes considered if the patient shows signs of worsening.

Causes of Pulmonary Embolism

Blood clots lead to a pulmonary embolism when a piece of a clot, most often from a deep vein thrombosis (DVT) in the leg, breaks off, travels through the heart, and becomes lodged in a pulmonary artery, blocking blood flow. This process effectively transforms a localized issue in a vein into a critical, life-threatening blockage within the lung’s circulatory system. The journey of a clot from a peripheral vein to the pulmonary vasculature is a direct cause-and-effect chain of events that defines the pathophysiology of this condition.

About Deep Vein Thrombosis (DVT)

Deep Vein Thrombosis (DVT) is the medical condition characterized by the formation of a blood clot (thrombus) within a deep vein, most frequently occurring in the lower leg, thigh, or pelvis. These veins are located deep within the muscles, running alongside arteries, and are responsible for returning a significant volume of blood back to the heart.

DVT is the primary source of approximately 90% of all acute pulmonary embolisms, making its prevention and diagnosis a cornerstone of PE management. The blood clots that form in these deep veins are particularly dangerous because of their size and their direct pathway to the heart and lungs. When a fragment of this thrombus detaches from the vein wall, it is reclassified as an embolus. This embolus is then carried along by the venous blood flow, traveling upward through the progressively larger veins of the leg, into the inferior vena cava (the body’s largest vein), through the right side of the heart (right atrium and right ventricle), and is then pumped directly into the pulmonary arteries.

Since the pulmonary arteries progressively narrow as they branch out to supply the lungs with deoxygenated blood, the embolus eventually becomes trapped, causing an obstruction known as a pulmonary embolism. This blockage prevents blood from reaching the section of the lung supplied by that artery, leading to a lack of oxygenated blood for the body and increased pressure on the right side of the heart.

Primary Risk Factors for Developing Blood Clots

The primary risk factors for developing blood clots are broadly categorized into those causing venous stasis (slow blood flow), endothelial injury (damage to the vein lining), and hypercoagulability (blood that clots too easily). These three pillars, known collectively as Virchow’s Triad, encompass a wide range of conditions, behaviors, and genetic predispositions that significantly elevate an individual’s risk of forming a DVT, which can subsequently lead to a PE.

Prolonged Immobility and Venous Stasis: When the body is inactive for long periods, the calf muscles do not contract to help pump blood back to the heart. This slowing of blood flow, or venous stasis, allows clotting factors to accumulate and increases the likelihood of a thrombus forming. Key examples include long-haul travel (flights or car rides exceeding four hours), hospitalization or bed rest after surgery or illness, and paralysis from spinal cord injury.
Surgery and Endothelial Injury: Major surgery, particularly orthopedic procedures involving the hip or knee, is a significant risk factor. The surgical process itself can damage the inner lining (endothelium) of the veins. When the endothelium is injured, it exposes underlying tissues that activate the body’s clotting cascade. The subsequent immobility during recovery further compounds this risk. Trauma from serious injuries, such as fractures, can also cause direct vessel damage.
Medical Conditions and Hypercoagulability: Certain medical conditions make the blood more prone to clotting. Cancer is a major risk factor, as some tumors release pro-coagulant substances. Heart failure and chronic obstructive pulmonary disease (COPD) can lead to blood pooling and stasis. Inflammatory conditions like Crohn’s disease or rheumatoid arthritis can also increase clotting risk. Furthermore, inherited conditions, known as thrombophilias (e.g., Factor V Leiden mutation), create a genetic predisposition for excessive clotting.
Lifestyle and Hormonal Factors: Other significant risk factors include obesity, which increases pressure in the veins and promotes inflammation; smoking, which damages blood vessel linings and affects coagulation; and age, with risk increasing significantly after 40. Hormonal factors also play a role; estrogen-based medications like birth control pills or hormone replacement therapy can increase the concentration of clotting factors in the blood. Pregnancy also elevates risk due to hormonal changes and the pressure of the growing uterus on pelvic veins.

Symptoms of Pulmonary Embolism

The critical warning signs of a pulmonary embolism are the sudden and unexplained onset of severe shortness of breath, sharp chest pain that worsens with deep inhalation, and a persistent cough that may produce bloody sputum. The symptoms often appear without warning and can vary dramatically in intensity depending on the size of the clot, the extent of the lung involved, and the individual’s underlying health status. Recognizing these classic symptoms is crucial because a PE is a medical emergency that requires immediate evaluation and treatment to prevent potentially fatal outcomes.

Common Symptoms of a PE

The most common symptoms of a pulmonary embolism are sudden dyspnea (shortness of breath), pleuritic chest pain, and a cough, which together form a classic triad, although not all three are present in every case. These symptoms are a direct result of the blockage in the pulmonary artery and the body’s physiological response to it. Understanding each symptom provides insight into the underlying medical crisis.

Sudden, Unexplained Shortness of Breath (Dyspnea): This is the most frequently reported symptom of PE. The blockage in the pulmonary artery prevents a portion of the lung from participating in gas exchange. As a result, the blood is not properly oxygenated, and the body senses this oxygen deficit. The brain responds by increasing the respiratory rate and creating a sensation of being unable to get enough air, even while at rest. This dyspnea is characteristically abrupt in its onset.
Sharp, Stabbing Chest Pain (Pleuritic Pain): This type of pain is another hallmark symptom. It occurs when the clot lodges in a peripheral artery near the lung’s surface, causing inflammation of the pleura, the two-layered membrane surrounding the lungs. The friction between these inflamed layers during breathing causes a sharp, localized pain that is markedly worse when taking a deep breath, coughing, or sneezing.
Cough and Hemoptysis: A persistent, often dry cough can accompany a PE. In some cases, the inflammation and high pressure in the pulmonary vessels can cause minor bleeding into the airways, leading to hemoptysis – coughing up blood or blood-streaked sputum. While less common than dyspna and chest pain, its presence is a significant red flag.
Other Important Signs: In addition to the classic triad, individuals may experience a rapid or irregular heartbeat (tachycardia or arrhythmia) as the heart works harder to pump blood through the obstructed arteries. Other signs can include lightheadedness, dizziness, or fainting (syncope), which occur when the blockage is large enough to severely compromise cardiac output and blood pressure. Swelling, pain, or redness in one leg (usually the calf) may also be present, indicating the source DVT.

Pulmonary Embolism Without Symptoms

A pulmonary embolism can absolutely occur without any noticeable symptoms, a condition often referred to as a silent PE. This situation is particularly dangerous because the absence of classic warning signs like chest pain or shortness of breath means the individual does not seek medical attention, allowing the underlying condition to go undiagnosed and untreated.

Silent PEs are more common when the blood clots are small. These smaller emboli may travel to and block smaller, peripheral branches of the pulmonary arteries. Because they obstruct only a minor portion of the lung’s blood supply, they may not cause a significant enough physiological disruption to produce overt symptoms. The body’s reserve capacity can often compensate for these minor blockages, masking the problem.

However, the lack of symptoms does not mean a silent PE is benign. Each embolic event, regardless of its size, causes some degree of damage to the lung tissue (infarction) and puts strain on the cardiovascular system. Moreover, a silent PE often signals the presence of an underlying DVT, which can continue to release more clots. A small, asymptomatic PE can be a precursor to a much larger, life-threatening embolism.

Often, these silent PEs are discovered incidentally during imaging tests, such as a CT scan, performed for other medical reasons. The discovery of a silent PE necessitates a full medical workup to identify the source of the clot and to initiate treatment, typically with anticoagulant therapy, to prevent future, more severe embolic events. This highlights the importance of assessing risk factors for DVT and PE, as individuals at high risk may harbor this silent but serious condition.

Pulmonary Embolism Diagnosis and Management

Key considerations for diagnosing and managing a Pulmonary Embolism involve a rapid and accurate diagnostic process using specific tests, implementing preventative strategies for high-risk individuals, understanding the long-term prognosis post-treatment, and classifying the event’s severity to guide therapy. Furthermore, these elements work in concert to create a comprehensive approach that starts before a PE ever occurs and extends far into the recovery period, ensuring patient safety and improving outcomes. The management strategy is highly individualized, taking into account the patient’s overall health, the underlying cause of the clot, and the physiological impact of the embolism on the heart and lungs.

How to Diagnose Pulmonary Embolism

An official diagnosis of a Pulmonary Embolism (PE) is a multi-step process that begins with a clinical assessment of symptoms and risk factors but ultimately relies on definitive testing to confirm the presence of a clot. Initially, healthcare providers use scoring systems like the Wells score to estimate the probability of a PE. Based on this risk assessment, a D-dimer blood test may be ordered. This test measures a substance released when a blood clot breaks down. A negative D-dimer result in a low-risk patient effectively rules out a PE. However, a positive result is not specific to PE, as it can be elevated in many other conditions, necessitating further imaging studies to confirm the diagnosis.

The gold standard for diagnosing a PE is a CT pulmonary angiography (CTPA). This non-invasive imaging test involves injecting a contrast dye into the veins and then using a computed tomography (CT) scanner to create detailed, cross-sectional images of the pulmonary arteries. The contrast dye makes the blood vessels visible, allowing radiologists to see any blockages clearly. For patients who cannot receive contrast dye due to kidney problems or an allergy, a Ventilation/Perfusion (V/Q) scan is an alternative.

This nuclear medicine scan compares the airflow (ventilation) to the blood flow (perfusion) in the lungs. A mismatch, where an area of the lung has good airflow but poor blood flow, is a strong indicator of a PE. To identify the source of the clot, doctors often perform a compression ultrasound of the legs to search for deep vein thrombosis (DVT), as over 90% of PEs originate from clots in the legs.

How to Prevent a Pulmonary Embolism

Prevention strategies are centered on mitigating the factors that contribute to clot formation, such as immobility, surgery, and certain medical conditions. For hospitalized patients, especially those undergoing major surgery (like orthopedic procedures) or who are confined to bed for extended periods, preventative measures are standard practice. These often involve a combination of mechanical and pharmacological methods to ensure blood continues to flow smoothly through the veins.

Prophylactic measures are crucial in preventing the initial deep vein thrombosis (DVT) that often leads to a PE. These preventative strategies are tailored to the individual’s specific risk profile.

Pharmacological Prophylaxis: For many high-risk individuals, especially after surgery or during a prolonged hospital stay, doctors prescribe low-dose anticoagulant medications. These drugs, such as heparin or low-molecular-weight heparin, are given as injections to thin the blood just enough to prevent clots without causing significant bleeding.
Mechanical Prophylaxis: Graduated compression stockings are frequently used. These specialized socks apply gentle pressure to the legs, helping to squeeze the veins and promote blood flow back to the heart. Another common device is an intermittent pneumatic compression (IPC) device, which consists of inflatable sleeves worn on the legs that regularly inflate and deflate to mimic the muscle contractions of walking.
Lifestyle and Behavioral Changes: For the general population, especially during long periods of inactivity like extended travel by plane or car, simple actions can significantly reduce risk. These include getting up to walk around every one to two hours, performing in-seat leg exercises (such as ankle circles and foot pumps), staying well-hydrated, and avoiding restrictive clothing.

Treatment for Pulmonary Embolism

The primary medical interventions for a pulmonary embolism focus on using anticoagulant medications to prevent new clots, applying advanced therapies like thrombolytics to dissolve large existing clots, and utilizing surgical or catheter-based procedures for severe cases. The immediate goals of treatment are to stabilize the patient, prevent the current clot from growing larger, stop the formation of additional clots from the source DVT, and restore blood flow through the pulmonary arteries to relieve strain on the heart.

Types of Medications for Treating a PE

There are two main categories of medications used to treat a pulmonary embolism: anticoagulants, which are the cornerstone of therapy for nearly all patients, and thrombolytics, which are reserved for more severe, life-threatening cases. These drug classes work through fundamentally different mechanisms to manage the acute event and prevent its recurrence.

Anticoagulants (Blood Thinners): This is the most common and essential class of medication for treating PE. Their primary function is not to dissolve the existing clot but to prevent it from getting bigger and to stop new clots from forming in the veins. By halting the coagulation cascade, anticoagulants give the body’s own natural clot-dissolving system (fibrinolysis) time to gradually break down the existing embolus. Initial treatment often begins in the hospital with an injectable anticoagulant like heparin or low-molecular-weight heparin (LMWH), which work quickly. This is then transitioned to a long-term oral anticoagulant for continued treatment, typically lasting at least three to six months. Options for oral anticoagulants include the traditional medication warfarin (Coumadin), which requires regular blood monitoring, or the newer Direct Oral Anticoagulants (DOACs) such as apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa), which are often preferred due to their fixed dosing and fewer interactions.
Thrombolytics (Clot Busters): These are powerful, potent drugs designed to actively and rapidly dissolve existing blood clots. The most common thrombolytic agent is tissue plasminogen activator (tPA). Unlike anticoagulants, thrombolytics work by activating plasminogen to form plasmin, an enzyme that directly breaks down the fibrin meshwork of the clot, thereby restoring blood flow quickly. Because of their potency, they carry a significantly higher risk of serious bleeding, including intracranial hemorrhage. Therefore, their use is reserved for patients with a massive PE who are hemodynamically unstable, meaning they have dangerously low blood pressure or signs of shock, where the immediate risk of death from the clot outweighs the risk of bleeding from the medication.

Anticoagulants vs. Thrombolytics

Anticoagulants and thrombolytics differ fundamentally in their mechanism of action, therapeutic goal, and clinical application: anticoagulants are used for prevention and stabilization, while thrombolytics are used for active dissolution of life-threatening clots. This distinction is critical in determining the appropriate treatment strategy for a patient with a pulmonary embolism. Anticoagulants, often called blood thinners, do not actually thin the blood or break down existing clots. Instead, they work by interfering with the body’s complex clotting cascade, which is the series of chemical reactions that lead to the formation of a fibrin clot.

By inhibiting specific clotting factors, medications like heparin and warfarin effectively press the pause button on clot formation. This prevents the existing embolus in the lung from growing larger and, crucially, stops the formation of new thrombi in the legs or elsewhere. The therapeutic goal is to stabilize the situation and allow the body’s own fibrinolytic system to slowly break down the clot over days to weeks. They are the standard of care for the vast majority of PE patients who are hemodynamically stable.

In stark contrast, thrombolytics, or clot busters, are designed for aggressive, rapid intervention. Their mechanism is to actively dissolve the clot that is already causing the life-threatening blockage. Drugs like tPA accomplish this by converting plasminogen into plasmin, the body’s primary clot-dissolving enzyme. This process, known as thrombolysis, rapidly degrades the fibrin structure of the clot, restoring blood flow through the obstructed pulmonary artery.

The therapeutic goal is immediate reperfusion to reverse shock and prevent death. Due to their potent effect, thrombolytics carry a high risk of major bleeding throughout the body. Consequently, their use is strictly limited to patients with massive or submassive PE who show signs of hemodynamic instability, such as persistent hypotension or right heart strain. In essence, anticoagulants play a defensive role (preventing worsening), while thrombolytics play an offensive role (actively attacking the clot).

Long-term Outlook After Surviving a PE

The long-term outlook after surviving a Pulmonary Embolism is generally positive, provided the condition is diagnosed and treated promptly and the patient adheres to follow-up care. The cornerstone of long-term management is anticoagulant therapy, or blood thinners. Most patients are prescribed these medications for a minimum of three to six months. The exact duration depends on the circumstances of the PE; if it was provoked by a temporary risk factor like surgery or immobility, a shorter course may be sufficient. However, if the PE was unprovoked or if the patient has an ongoing risk factor (such as a genetic clotting disorder), lifelong anticoagulation may be recommended to prevent a recurrence.

While most patients recover fully, a subset may experience lingering symptoms known as post-PE syndrome. This can include persistent shortness of breath, chest pain, and a reduced capacity for exercise, which can impact quality of life. A much rarer but more severe long-term complication is chronic thromboembolic pulmonary hypertension (CTEPH). This condition occurs in a small percentage of PE survivors (approximately 1-4%) when the blood clots in the pulmonary arteries do not dissolve completely.

Instead, they organize into scar-like tissue that permanently narrows or blocks the arteries. This blockage increases the pressure in the pulmonary arteries, forcing the right side of the heart to work harder to pump blood to the lungs. Over time, this can lead to right-sided heart failure. CTEPH requires specialized treatment, which may include surgery (pulmonary thromboendarterectomy) to remove the scarred tissue or medications to manage the high blood pressure in the lungs.

FAQs

1. How do you tell if you have a pulmonary embolism?

Pulmonary embolism often presents with sudden and noticeable symptoms, though they can vary in intensity. The most common signs include shortness of breath, sharp chest pain that may worsen with deep breathing, a rapid heartbeat, and unexplained coughing, sometimes with blood. Some people also experience dizziness, sweating, or fainting. Because these symptoms can resemble other conditions, PE is often difficult to recognize without medical testing. If these signs appear suddenly, especially in combination, it is important to seek immediate medical attention.

2. Can you fully recover from pulmonary embolism?

Yes, many people can fully recover, especially with early diagnosis and proper treatment. Blood thinners and other therapies help prevent new clots while the body gradually breaks down existing ones. Recovery time varies depending on the size of the clot and overall health. Some individuals may experience lingering symptoms, but with follow-up care and lifestyle adjustments, long-term outcomes are often positive.

3. What is the best treatment for pulmonary embolism?

The primary treatment is anticoagulant medication (blood thinners), which prevents clots from growing and reduces the risk of new ones forming. In more severe cases, doctors may use clot-dissolving drugs (thrombolytics) or perform procedures to remove the clot. Oxygen therapy and supportive care are also used when needed. The best treatment depends on how severe the embolism is and how stable the patient is at the time of diagnosis.

4. How long can you have a pulmonary embolism without knowing?

In some cases, a small pulmonary embolism can go unnoticed for days or even weeks, especially if symptoms are mild or mistaken for something else. However, even when symptoms seem minor, the condition can worsen quickly. That unpredictability is what makes PE so dangerous and why early evaluation is critical.

5. How painful is a pulmonary embolism?

The pain can vary, but it is often described as a sharp, stabbing chest pain, especially when breathing deeply or coughing. Some people experience only mild discomfort, while others feel intense pain that can be frightening. The severity depends on the size and location of the clot.

Conclusion

Pulmonary embolism is a condition that does not give much warning, yet its impact can be immediate and severe. What begins as a small clot can quickly become a life-threatening blockage, making awareness one of the most important tools you have. Understanding the causes, recognizing the symptoms, and knowing when to act can make a critical difference. Many cases are treatable, and recovery is possible, but timing matters. The earlier the condition is identified, the better the chances of avoiding serious complications.

Your body often sends signals before a situation becomes critical. Paying attention to sudden shortness of breath, chest pain, or unusual discomfort is not overreacting, it is protecting your life. When it comes to pulmonary embolism, acting quickly is not just important, it can be lifesaving.

References:

Disclaimer This article is intended for informational and educational purposes only. We are not medical professionals, and this content does not replace professional medical advice, diagnosis, or treatment. The goal is to provide accurate, evidence-based information to raise awareness of causes of pancreatitis. If you are experiencing persistent, severe, or concerning symptoms, you should seek guidance from a qualified healthcare provider. Read the full Disclaimer here →

Pulmonary Embolism (PE): Causes, Symptoms, Diagnosis, and Treatment

What is Pulmonary Embolism?